Immune checkpoints are a key class of protein regulators that work in keeping the immune system in balance. They prevent in autoimmunity against own tissues and the immune inhibitory pathways are intrinsically hardwired into the immune system. Cancerous cells exploit this function as an evasive strategy in masking their presence amidst the immune system. Tumors overexpress proteins that are involved in such pathways like programmed cell death protein 1 (PD-1), its ligand (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Immune checkpoints are thus a key area of exploration for understanding cancer resistance and targets for cancer therapeutics. Screening for the expression levels of PD-1 and PD-L1 in FFPE tissues are gaining attention and its implication are strong.
BioGenex is pleased to announce the launch of PD-1 and PD-L1 monoclonal antibodies for immunohistochemistry (IHC) biomarker screening. The ready-to-use (RTU) and concentrated formats of the antibodies are certified for in vitro diagnostics (IVD) and CE marked.